Study With Vortioxetine on Emotional Functioning in Patients With Depression

Major Depressive Disorder Clinical Trial

— COMPLETE  

Official title:

Interventional, Open-label, Flexible-dose Study of Vortioxetine on Emotional Functioning in Patients With Major Depressive Disorder With Inadequate Response to SSRI/SNRI Treatment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03835715
• Other study ID #: 17797A
• Status: Completed
• Phase: Phase 4
• Start date: February 5, 2019
• Est. completion date: February 21, 2020

Study information

• Verified date: February 2020
• Source: H. Lundbeck A/S
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study will evaluate effectiveness of flexible dose vortioxetine 10-20 mg/day on emotional functioning in patients with MDD with an inadequate response to SSRIs/SNRIs.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: February 21, 2020
• Est. primary completion date: February 21, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• The patient has a primary diagnosis of single or recurrent MDD according to DSM-5®. The current major depressive episode (MDE) must be confirmed using the Mini International Neuropsychiatric Interview (MINI).

• The patient has had the current MDE for <12 months.

• The patient has a Montgomery and Åsberg Depression Rating Scale (MADRS) total score = 22 and = 28 at the Baseline Visit.

• The patient has been treated with SSRI/SNRI monotherapy (citalopram, escitalopram, paroxetine, duloxetine or venlafaxine) for at least 6 weeks at adequate dose for the current MDE and with an inadequate response and is a candidate for a switch in the investigator's opinion.

• The patient wants to switch antidepressant treatment.

• The patient has an ODQ total score =50 at baseline, while on SSRI/SNRI monotherapy (prior to switch).

• The patient answered "Yes "to the screening question on emotional effects.

Exclusion Criteria:

• The patient has a significant risk of suicide according to the investigator's clinical judgment or has made an actual suicide attempt in the previous 6 months prior to Baseline

Other in- and exclusion criteria may apply

Related Conditions & MeSH terms

• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Drug:
• Vortioxetine
Flexible doses (10-20 mg) of vortioxetine; 10 mg during the first week which may be increased up to 20 mg week 2-8

Locations

Country	Name	City	State
France	Office of Dr. Patrick Bourgoin (FR0011)	Angoulême
France	Cabinet Psyche (FR0012)	Douai
France	Centre Medical Ambroise Pare (FR0007)	Élancourt
France	Dr. David Modavi Md, Office Of (FR0001)	Toulouse
France	Private Practice Dr. Paule Khalifa (FR0010)	Toulouse
France	GHS De Nancy - CPN Laxou (FR0006)	Vandœuvre-lès-Nancy
France	Dr Karim Boutayeb MD, Office of (FR0009)	Viersat
Italy	DSM Giulianova c/o ospedale di Giulianova (IT0004)	Giulianova
Italy	Dipartimento Salute Mentale ASL Lecce (IT0006)	Lecce
Italy	Universita degli Studi di Roma La Sapienza - Azienda Ospedaliera Sant Andrea (IT0013)	Rome
Lithuania	JSC Romuvos Klinika (LT0002)	Kaunas
Lithuania	Mental Health Centre Kaunas Outpatient Clinic (LT0005)	Kaunas
Lithuania	JSC Nefridos klinika (LT0006)	Klaipeda
Lithuania	Jsc Silutes Mental Health And Psychotherapy Center (LT0001)	Silute
Lithuania	Antakalnis Psychiatric Consultation Centre (LT0003)	Vilnius
Lithuania	PI Mental Health Center of Zirmunai (LT0004)	Vilnius
Spain	Hospital Universitario Fundacion Alcorcon (ES0009)	Alcorcón
Spain	Instituto Internacional de Neurociencias Aplicadas (ES0004)	Barcelona
Spain	Centro De Salud Mental De Foios (ES0002)	Foios
Spain	University of Oviedo (ES0011)	Oviedo
Spain	Francesca Canellas Dols (ES0005)	Palma De Mallorca
Spain	Hospital Clínico Universiatrio de Salamanca (ES0001)	Salamanca
Spain	Centro De Especialidades A Doblada (ES0006)	Vigo

Sponsors (1)

Lead Sponsor	Collaborator
H. Lundbeck A/S

Countries where clinical trial is conducted

France,  Italy,  Lithuania,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline to Week 8 in Oxford Depression Questionnaire (ODQ) total score	The ODQ is a patient-centred, self-report measure of emotional symptoms present in patients treated with antidepressants. The ODQ is a 26-item patient self-complete measure, spread over 3 sections and covering 5 dimensions of: not caring (NC), emotional detachment (ED), positive reduction (PR), general reduction (GR), and antidepressant as cause (AC). Response options are based on 5-point Likert scale with a score applied to each response.	From baseline to Week 8
Secondary	Change from baseline to Week 8 in MEI total score.	The Motivation and Energy Inventory (MEI) is a 27-item scale initially developed and validated for the purpose of evaluating interventions to improve motivation and energy in patients with depression. The MEI assesses three domains: mental or cognitive energy, social motivation, and physical energy. Scoring Respondents use scales ranging from 0 (indicating that the behavior is never present) to 5 or 6 (a behavior or feeling that is present very frequently or all of the time). Items 3-11, 13-15, 17, and 18 are reverse-scored in order to ensure that higher scores indicate greater levels of motivation and energy. All items use either a 5- or 7-point Likert type response scale.	From baseline to Week 8
Secondary	Change from baseline to Week 8 in DSST total score	The Digit-Symbol Substitution Test (DSST) is a cognitive test designed to assess psychomotor speed of performance requiring visual perception, spatial decision-making and motor skills. The DSST is sensitive to cognitive impairments affecting attention, processing speed, and executive function (including working memory). The DSST consists of 133 digits and requires the subject to substitute each digit with a simple symbol in a 90-second period. Each correct symbol is counted. The total score is the number of correct symbols and the total score ranges from 0 (less than normal functioning) to 133 (greater than normal functioning).	From baseline to Week 8
Secondary	Change from baseline to Week 8 in ODQ domain scores (NC, ED, PR, GR, and AC)	The Oxford Depression Questionnaire (ODQ) is a patient-centred, self-report measure of emotional symptoms present in patients treated with antidepressants. The ODQ is a 26-item patient self-complete measure, spread over 3 sections and covering 5 dimensions of: not caring (NC), emotional detachment (ED), positive reduction (PR), general reduction (GR), and antidepressant as cause (AC). Response options are based on 5-point Likert scale with a score applied to each response.	From baseline to Week 8
Secondary	Change from baseline to Week 8 in MADRS total score	The Montgomery and Åsberg Depression Rating Scale (MADRS) is a 10-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). The total score of the 10 items ranges from 0 to 60, with higher values indicating worse outcome.	From baseline to Week 8
Secondary	Change from baseline to Week 8 in SDS individual item scores (family, work, and social life)	Sheehan Disability Scale (SDS) measures disability. Total scores are computed by summing scores from all 3 items. Total score ranges from 0 to 30, with higher scores indicating greater disability. Reduction in SDS scores therefore indicates better outcome.	From baseline to Week 8
Secondary	Change from baseline to Week 8 in SDS total scores	Sheehan Disability Scale (SDS) measures disability. Total scores are computed by summing scores from all 3 items. Total score ranges from 0 to 30, with higher scores indicating greater disability. Reduction in SDS scores therefore indicates better outcome.	From baseline to Week 8
Secondary	Change from baseline to Week 8 in CGI-S score	The Clinical Global Impression severity of illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).	From baseline to Week 8
Secondary	CGI-I score at Week 8	The Clinical Global Impression - global improvement CGI-I provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.	at Week 8